193 Results

People

  1. Robson
    Robson
  2. Offit
    Offit
  3. Stadler
    Stadler
  4. Joseph
    Joseph
  5. Jones
    Jones
  6. Walsh
    Walsh
  7. Saltz
    Saltz
  8. Hudis
    Hudis
  9. Cercek Hanjis
    Cercek Hanjis
  10. Goldfarb
    Goldfarb

Groups

  1. Department of Medicine (193)
  2. Population Sciences Research Program (193)
  3. Solid Tumor Oncology Division (193)
  4. Survivorship Research (145)
  5. Breast Medicine Service (93)
  6. Epidemiology and Biostatistics (76)
  7. GSK Faculty (68)
  8. Surgery (60)
  9. Clinical Genetics Service (57)
  10. Biostatistics Service (55)
  1. "2017"
  2. "Solid Tumor Oncology Division"
  3. "Population Sciences Research Program"
Formats
  1. Journal Article (127)
  2. Meeting Abstract (66)
Groups
  1. Department of Medicine (193)
  2. Population Sciences Research Program (193)
  3. Solid Tumor Oncology Division (193)
  4. Survivorship Research (145)
  5. Breast Medicine Service (93)
  6. Epidemiology and Biostatistics (76)

More Groups

People
  1. Mark Robson (47)
  2. Kenneth Offit (31)
  3. Zsofia Stadler (20)
  4. Michael Berger (16)
  5. Vijai Joseph (16)
  6. Lee Jones (15)

More People

Years
  1. 2017 (193)
Publications
  1. Journal of Clinical Oncology (33)
  2. Cancer Research (12)
  3. Clinical Cancer Research (11)
  4. Breast Cancer Research and Treatment (6)
  5. Annals of Oncology (5)
  6. Blood (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (39)
  2. American Association for Cancer Research (24)
  3. Elsevier Inc. (18)
  4. Springer (17)
  5. Nature Publishing Group (14)
  6. Oxford University Press (14)

More Publishers

Results (193)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PTEN loss-of-function alterations are associated with intrinsic resistance to BRAF inhibitors in metastatic melanoma
    Journal Article

    Catalanotti, F.; Cheng, D. T.; Shoushtari, A. N.; Johnson, D. B.; Panageas, K. S.; Momtaz, P.; Higham, C.; Won, H. H.; Harding, J. J.; Merghoub, T.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making
    Journal Article

    Abida, W.; Armenia, J.; Gopalan, A.; Brennan, R.; Walsh, M.; Barron, D.; Danila, D.; Rathkopf, D.; Morris, M.; Slovin, S.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • Decision-making preferences about secondary germline findings that arise from tumor genomic profiling among patients with advanced cancers
    Journal Article

    Hamilton, J. G.; Shuk, E.; Garzon, M. G.; Rodríguez, V. M.; Westerman, J.; Hay, J. L.; Offit, K.; Robson, M. E.
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • Determining the prevalence of germline BAP1 mutations in malignant mesothelioma (MM)
    Meeting Abstract

    Zauderer, M. G.; DuBoff, M. A.; Siegel, B.; Robson, M. E.; Arnold, A. G.; Berliner, J.; Fleischut, M. H.; Mandelker, D.; Ladanyi, M.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Longer follow-up on cardiac safety and distant disease free survival of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab in patients with early-stage HER2-positive breast cancer
    Meeting Abstract

    Wang, R.; Yu, A. F.; Steingart, R.; Patil, S.; Baselga, J.; Norton, L.; Hudis, C.; Dang, C. T.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO)
    Meeting Abstract

    Turner, N. C.; Telli, M. L.; Rugo, H. S.; Mailliez, A.; Ettl, J.; Grischke, E. M.; Mina, L. A.; Gelpi, J. B.; Fasching, P. A.; Hurvitz, S. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Protection from late-occurring anthracycline-related cardiotoxicity among childhood cancer survivors with a RARG coding variant
    Meeting Abstract

    Tonorezos, E. S.; Joseph, V.; Barnea, D.; Villano, D.; Satagopan, J.; Friedman, D. N.; Sklar, C. A.; Oeffinger, K. C.; Offit, K.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinical and immunologic variables associated with outcomes following combination ipilimumab and nivolumab immunotherapy in melanoma
    Meeting Abstract

    Rosner, S.; Kwong, E.; Panageas, K.; Postow, M. A.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
    Meeting Abstract

    Robson, M. E.; Im, S. A.; Senkus, E.; Xu, B.; Domchek, S. M.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N. M.; Armstrong, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast, lung, and prostate cancer
    Meeting Abstract

    Razavi, P.; Li, B.; Abida, W.; Aravanis, A.; Jung, B.; Shen, R.; Hou, C.; De Bruijn, I.; Gnerre, S.; Lim, R. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save